Because DRMA lacks the multiple credible current targets needed to build a meaningful average, the $4 objective used here comes from identifiable public discussion rather than a calculated consensus. The single active analyst target is Maxim Group's $4.00, maintained by analyst Anthony Vendetti with a Buy rating in August 2026. Maxim had cut the target to $4 from $10 in April 2026, citing share dilution and a wider fourth-quarter GAAP loss per share. This illustrates a core point: the target reflects a post-reverse-split, pre-revenue company whose valuation is highly sensitive to capital raises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Dermata shares have recently traded around $0.78, giving the company a market capitalization of only about $5 million. Reaching $4 would require a gain of roughly 400%, a very large move by any standard. The stock completed a 1-for-10 reverse split in August 2025 and has since traded in a wide range, remaining near the lower end of its 52-week span. With no product revenue and limited institutional ownership, the path to $4 would almost certainly depend on successful commercialization of the Tome skincare line, a credible revenue trajectory, and additional capital raised on less dilutive terms — a combination the company has not yet demonstrated.
The bull case rests on validated science and a faster market route. Dermata's lead candidate, XYNGARI, met its primary endpoint in the Phase 3 STAR-1 trial for moderate-to-severe acne in early 2025, supporting the mechanism of its Spongilla lacustris-derived "Bioneedle" technology. Management's September 2025 pivot to over-the-counter (OTC) and direct-to-consumer (DTC) skincare avoids the multi-year, costly FDA new drug approval process, targeting the roughly 50 million U.S. acne patients with a potentially premium product. Cost discipline is evident: operating expenses fell about 38% in 2025, and the company held cash and equivalents of $4.4 million at mid-2026 with plans for a product launch in August 2026.
The risks are substantial and largely structural. Dermata has generated no revenue and posted a 2025 net loss of $7.56 million, with an accumulated deficit near $78 million. Its auditor has included a going-concern warning, and management expects to need additional financing — a recurring source of dilution that directly erodes per-share value. The company relies on a single supplier, Reka-Farm LLC in Russia, for its core sponge ingredient, exposing it to geopolitical and supply-chain disruption. Regulatory uncertainty remains: if regulators classify the Bioneedle as an active ingredient rather than an inactive one, an OTC monograph path could be blocked. A terminated licensing agreement with Villani Inc. adds litigation risk, while an unproven consumer brand must compete against large, well-funded skincare incumbents.
The long-term trend remains negative. Following the 1-for-10 reverse split, shares have continued to trade below their 200-day moving average, a durable sign of persistent downtrend, even as shorter-term moving averages have at times turned constructive. With a 52-week range spanning roughly $0.95 to $5.98 and a market cap near $5 million, liquidity is thin, meaning any move — up or down — can be amplified. Psychological whole-dollar levels such as $1 and $2 would be notable milestones, but the stock currently sits far below them. From what I see, monitoring these levels closely helps put potential moves in context.
Analyst price targets are typically set on a roughly 12-month research horizon, though Maxim's target predates the company's commercial launch and may not reflect a specific timing assumption. The items that matter most are the success of the August 2026 Tome product launch, the first signs of actual revenue, quarterly cash burn and any capital raises, the resolution of the Villani licensing dispute, and FDA positioning around the OTC monograph. Because Dermata's runway extends only into late 2026 or early 2027, financing news will likely move the shares as much as, or more than, operating results. I’m watching this closely as developments unfold.
AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a thinly traded micro-cap like Dermata, where sentiment can turn quickly, these signals can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Traders interested in a data-driven complement to fundamental research may find the tool a useful way to stay ahead of fast-moving price action. In my view, this has become a regular part of how I review positions like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DRMA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 91 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DRMA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 53 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DRMA entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRMA advanced for three days, in 148 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
DRMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.085) is normal, around the industry mean (3.596). P/E Ratio (-0.182) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. DRMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology